Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

• Asıl Yazarlar: Hoai‐Thu Thai (Yazar), Kimiko Koiwai (Yazar), Yoshihisa Shitara (Yazar), Hirotaka Kazama (Yazar), Jean‐Baptiste Fau (Yazar), Dorothée Semiond (Yazar), Christine Veyrat‐Follet (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2023-12-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of serum M‐protein kinetics and its association with p...